drugset / Trial / NCT01710631

Twelve Month Study of the Safety of Eszopiclone in Adult Subjects With Insomnia

NCT01710631

Phase 3 Completed 791 enrolled Sumitomo Pharma America, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A six-month study to determine the safety and efficacy with an additional open-label extension to determine the long-term safety of eszopiclone in the treatment of adult subjects with primary insomnia.

Timeline

Start
2001-02
Primary completion
2002-08
Completion
2002-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Eszopiclone Small molecule 3 mg

Indications